Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR) in type 2 diabetic patients and their contributing factors. Methods: 199 type 2 ...

The convergence of advanced technologies and advancements in drug delivery is reshaping diabetes care. Digital therapeutics ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy recommendation. Analyst Price Forecast Suggests 265.47% Upside As of ...

Background: Gestational diabetes mellitus (GDM) is a temporary metabolic disorder in which small retinal vessels may have experience subtle changes before clinical lesions of the fundus retina appear.

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Michael S.

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.